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Randomized Comparison of Primary Stenting and
Provisional Balloon Angioplasty Guided by Flow
Velocity Measurement
Patrick W. Serruys, MD; Bernard de Bruyne, MD; Stéphane Carlier, MD; José Eduardo Sousa, MD;
Jan Piek, MD; Toshiya Muramatsu, MD; Chris Vrints, MD; Peter Probst, MD;
Ricardo Seabra-Gomes, MD; Ian Simpson, MD; Vasilis Voudris, MD; Olivier Gurné, MD;
Nico Pijls, MD; Jorge Belardi, MD; Gerrit-Anne van Es, PhD; Eric Boersma, PhD;
Marie-Angèle Morel, MS; Ben van Hout, PhD; on behalf of the Doppler Endpoints Balloon
Angioplasty Trial Europe (DEBATE) II Study Group
Background—Coronary stenting improves outcomes compared with balloon angioplasty, but it is costly and may have
other disadvantages. Limiting stent use to patients with a suboptimal result after angioplasty (provisional angioplasty)
may be as effective and less expensive.
Methods and Results—To analyze the cost-effectiveness of provisional angioplasty, patients scheduled for single-vessel
angioplasty were first randomized to receive primary stenting (97 patients) or balloon angioplasty guided by Doppler
flow velocity and angiography (523 patients). Patients in the latter group were further randomized after optimization to
either additional stenting or termination of the procedure to further investigate what is “optimal.” An optimal result was
defined as a flow reserve .2.5 and a diameter stenosis ,36%. Bailout stenting was needed in 129 patients (25%) who
were randomized to balloon angioplasty, and an optimal result was obtained in 184 of the 523 patients (35%). There was
no significant difference in event-free survival at 1 year between primary stenting (86.6%) and provisional angioplasty
(85.6%). Costs after 1 year were significantly higher for provisional angioplasty (EUR 6573 versus EUR 5885;
P50.014). Results after the second randomization showed that stenting was also more effective after optimal balloon
angioplasty (1-year event free survival, 93.5% versus 84.1%; P50.066).
Conclusions—After 1 year of follow-up, provisional angioplasty was more expensive and without clinical benefit. The
beneficial value of stenting is not limited to patients with a suboptimal result after balloon angioplasty. (Circulation.
2000;102:2930-2937.)
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Over the last 2 decades, percutaneous transluminal coro-nary angioplasty has proven to be a safe and effective
option for treating patients with coronary artery disease.1
However, treatment results may be transient because of
recoil, restenosis, and reocclusion. Although these disadvan-
tages are partly overcome by coronary stenting,2–6 the costs
of coronary stenting are high compared with balloon angio-
plasty, and the long-term outcome remains a matter of
concern.7,8
It has been suggested that optimal balloon angioplasty
could yield a clinical outcome similar to stenting.9–12 The
See p 2910
Doppler Endpoints Balloon Angioplasty Trial Europe (DE-
BATE) I results support this hypothesis in that the outcome
for patients with both a diameter stenosis (DS) #35% and a
coronary flow reserve (CFR) .2.5 was comparable to that
achieved with stenting in the Belgian Netherlands Stent
(BENESTENT) trials.3,13 Thus, the following provisional
approach emerges: stent only those patients likely to reap an
additional benefit. Such an approach challenges the inter-
vener who must decide on overall patient care. “Provisional
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angioplasty” refers to a status of angioplasty that satisfies
predefined criteria of optimal results based on pressure
gradients,11 early loss of minimal lumen diameter,10 or
intravascular ultrasound measurements.12 A failure to meet
the criteria would change the intended treatment and results
in stent implantation.
DEBATE II was a prospective, randomized study that used
criteria identified in DEBATE I. It addressed the following
questions. (1) Should elective treatment be by stenting or
balloon angioplasty (provisional angioplasty being guided by
the stated criteria)? (2) What is the relative cost/benefit ratio
of these strategies? (3) Do patients with optimal balloon
angioplasty obtain an additional benefit from stenting?
Methods
Patient Selection
Patients were eligible for the study if they were scheduled to undergo
angioplasty for stable or unstable angina pectoris (excluding Braun-
wald classification III),14 documented myocardial ischemia due to a
single de novo coronary stenosis potentially amenable to stent
implantation, or both. The target lesion was to supply viable
myocardium and be ,25 mm long. Excluded patients manifested
total coronary occlusion; lesions that were ostial or at a bifurcation;
lesions in vessels that were previously bypassed, tortuous, or
contained thrombus; or previous Q-wave infarction (in the target
vessel territory or from an evolving myocardial infarction of the
previous week). The study was performed according to the principles
in the Declaration of Helsinki. Every patient provided written,
informed consent.
Study Objectives and Trial Design
The primary trial objective was to compare the cost-effectiveness of
elective stent implantation (primary stenting) with provisional bal-
Figure 1. Study flowchart. R1 indicates first randomization; R2,
second randomization; and BA, balloon angioplasty. Patient
groups with provisional stenting are framed in bold. Actual num-
ber of patients in clinical subsets lie between parentheses; theo-
retical assumptions are denoted by n. Twelve patients were
excluded from study between randomizations 1 and 2 (10 due
to inconsistencies between randomization service and investiga-
tors, and 2 due to missing CFR values).
TABLE 1. Baseline Clinical and Angiographic Characteristics
First Randomization
Primary
Stenting
Guided Balloon
Angioplasty
n 97 523
Male sex 72 73
Age, y 60610 59611
Previous conditions
Q-wave myocardial infarction 6 10
Non Q-wave myocardial infarction 18 17
Coronary artery bypass grafting 1 1
Angioplasty 9 11
Diabetes mellitus 10 10
Insulin-dependent 2 2
Hypertension 46 39
Hypercholesterolemia 48 53
Family history 43 38
History of stroke 2 2
Peripheral vascular disease 7 5
Smoking history
Never smoked 35 36
Previous smoker 38 37
Current smoker 27 27
Stable angina 59 58
Canadian Cardiovascular Society classification
1 5 5
2 32 31
3 19 20
4 3 2
Unstable angina 39 34
Braunwald classification14
IB 8 12
IIB 24 17
IC 4 2
IIC 3 3
Silent ischemia 2 8
No. of diseased vessels
1 91 90
2 9 8
3 0 2
Target vessel
Right coronary 26 30
Left anterior descending 61 53
Left circumflex 13 18
Lesion type27
A 12 18
B1 23 26
B2 59 51
C 6 6
DS,* % 70612 70611
Values are mean6SD or % of patients, unless otherwise indicated.
*Assessed by the investigator during the procedure.
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loon angioplasty guided by quantitative angiography and Doppler
flow velocity measurements. The strategy after provisional angio-
plasty was to limit stent implantation to bailout situations and cases
in which an “optimal result” (DS #35% and CFR .2.5)13 was not
achievable. The secondary objective was to evaluate the benefit
differences from additional stenting in patients with and without an
optimal result. Therefore, double randomization was required (Fig-
ure 1).
It would be incorrect to estimate the costs and benefits of
provisional angioplasty using average costs and benefits combining
(1) patients with bailout stents, (2) patients with optimal balloon
angioplasty, and (3) patients with stenting after a suboptimal result.
Patients left after bailout stenting would then receive too much
weight, because the bailout decision was made before the second
randomization, leading to 4 groups instead of the 2 created by the
provisional angioplasty strategy. Therefore, a weighted average was
used that weighted bailout stenting by the probability of bailout
stenting and stenting in patients who did not require bailout stenting
by the probabilities of belonging to either the optimal balloon
angioplasty or suboptimal angioplasty groups. Thus, the provisional
angioplasty group is a constructed or virtual group.
Primary Stenting
A conventional guidewire was used in patients randomized to
primary stenting, and predilatation was performed in all patients
before stent implantation.
Guided Balloon Angioplasty
During guided balloon angioplasty, quantitative angiography and
CFR measurements were made using standardized protocols13,15 to
achieve an optimal result (criteria defined earlier in article).
A 0.014-inch Doppler guidewire (Cardiometrics FloWire, EndoSon-
ics) was advanced distal to the lesion, and velocity recordings were
obtained under basal and hyperemic conditions. Maximal hyperemia
was induced by adenosine, which was administered as an intracoronary
bolus (right coronary artery, 12 mg; left coronary artery, 18 mg) or as an
intravenous infusion (140 mg z kg21 z min21).16,17 These 2 methods were
proven to be equivalent.
If an optimal result was not achieved, the operator was urged to
perform iterative dilatations by upsizing the balloon, increasing the
inflation pressure, or both. Bailout stenting was allowed in the
presence of residual stenosis .50%; dissection types D, E, or F;
persistent myocardial ischemia with dissection type C; reduction of
TIMI flow18 by $1 grade; or the existence of TIMI grades 0 or 1.
The final DS and CFR were assessed after an optimal result was
achieved or when the operator considered further improvement
attempts unsafe. A second randomization was then performed that
disregarded the measurements.
Efficacy End Points
The efficacy end point compiled major adverse cardiac events within
12 months of the procedure; these included death from any cause,
nonfatal myocardial infarction, and percutaneous or surgical target
lesion revascularization. Myocardial infarction was defined as the
development of a new Q-wave or a rise of serum creatinine kinases
with an abnormal plasma concentration of myocardial isoenzymes.
Enzymes were sampled twice in the first 24 hours. Patients visited
the outpatient clinic 1, 6, and 12 months after hospital discharge. At
each visit, records were kept of anginal status, cardiac medication,
12-lead ECG, and complete physical examination. No follow-up
angiogram was performed unless clinically indicated.
Figure 2. Relative role of DS and CFR in classifying patients in
balloon angioplasty group (bailout patients not included).
TABLE 2. Angiography and CFR During the Procedure
First Randomization
GBA
Bailout
GBA: Second Randomization
PS GBA
Stent:
Optimal
Stent:
Suboptimal
Balloon:
Optimal
Balloon:
Suboptimal
n 97 523 129 77 112 107 86
Initial DS, % 70612 70611 72611 67611 70611 69612 69611
Initial CFR z z z 1.660.6 1.660.6 1.760.6 1.560.6 1.760.6 1.460.4
DS before second randomization, % z z z z z z z z z 2268 2269 2368 24611
CFR before second randomization z z z z z z z z z 3.160.5 2.060.4 3.160.6 2.060.4
Lesion length, mm 964 964 963 964
Reference diameter, mm 2.7860.42 2.7360.44 2.7160.47 2.6260.45
Final DS, % 968 z z z z z z 868 768 z z z z z z
Stent length, mm 1564 1664 z z z z z z
Balloon length, mm z z z z z z 2062 2064
Final CFR z z z z z z z z z 3.360.7 2.460.7 z z z z z z
Values are mean6SD. PS indicates primary stenting; GBA, guided balloon angioplasty.
Twelve patients were excluded from the study after the first randomization: 10 patients due to inconsistencies between randomization service and investigators,
and 2 patients due to missing CFR values.
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Costs
Cost analysis was limited to direct medical costs, which were
calculated as resource utilization volume 3 unit costs in 1999 at the
University Hospital Rotterdam-Dijkzigt, the Netherlands.19 Re-
sources included the materials used in the initial procedure (eg,
stents, balloons, and Doppler wires); length of stay in the intensive
care unit, coronary care unit, or general ward; major curative and
diagnostic procedures; and rehospitalization within 12 months of the
initial procedure. Although it could be expected that a guided
strategy would lengthen procedures, we decided not to estimate the
cost consequences of such an action. We hypothesized that the
increased duration would not reduce the number of procedures
possible per day; thus, the “fixed costs” would remain fixed. Also,
the data may be biased by the time taken for a second randomization,
thus breaking the continuity of procedures.
Cost Effectiveness
The balance between costs and benefits was addressed by calculating
incremental cost-effectiveness ratios (ie, additional costs per addi-
tional event-free survivor after 1 year) and by estimating the
probabilities that the provisional angioplasty was (1) more effective
and cost saving, (2) more effective and more costly, (3) less effective
and cost saving, or (4) less effective and more costly.
Sample Size
Assumptions for sample size calculation were based on
BENESTENT-1, BENESTENT-2 pilot, and DEBATE I experienc-
es.2,3,13 All additional benefits of stenting were attributed to patients
with suboptimal results. With these assumptions, it was calculated
that for the randomization scheme in Figure 1, 600 patients were
needed to detect, with 80% power, a difference (a50.05) of EUR
680 between provisional angioplasty and primary stenting in cost-
effectiveness per survivor (no major adverse cardiac event) after 1
year.20
Statistical Analysis
Continuous variables are expressed as means6SD. Differences
between patient groups were studied using Student’s unpaired t test
or 1-way ANOVA, whichever was appropriate. Categorical variables
are presented as percentages, and differences between groups were
evaluated using Fisher’s exact test. Kaplan-Meier event-free survival
curves were calculated, and differences between patient groups were
compared by a log-rank test.
Figure 3. Event-free survival (Kaplan-Meier curves) at 12 months.
Patients with suboptimal and optimal balloon angioplasty were ran-
domized to additional stenting or no further treatment. OS indi-
cates optimal stenting (n577); SOS, suboptimal stenting (n5112);
OB, optimal balloon angioplasty (n5107); SOB, suboptimal balloon
angioplasty (n586); FE, Fisher’s exact test; and LR, log-rank test.
For definitions of optimal and suboptimal, see text.
Figure 4. Event-free survival (Kaplan-Meier curves) at 12
months in patients who had primary stenting (PRIM; n597) or
provisional angioplasty (PROV; n5523).
TABLE 3. Frequency of Primary Clinical End Points at 12 Months in Descending Order of Severity
First
Randomization
GBA
Bailout
GBA: Second Randomization
PS GBA
Stent:
Optimal
Stent:
Suboptimal
Balloon:
Optimal
Balloon:
Suboptimal
n 97 523 129 77 112 107 86
Death 2.1 1.3 0.8 2.6 0.9 0.9 2.3
MI 4.1 3.6 7.0 0.0 3.6 1.9 3.5
Q-wave 2.1 1.9 3.1 0.0 1.8 1.9 1.2
Non–Q-wave 2.1 1.7 3.9 0.0 1.8 0.0 2.3
CABG 0.0 1.1 2.3 0.0 0.9 0.9 0.0
TLPR 7.2 9.8 7.8 3.9 5.4 12.1 20.9
MACE-free 86.6 84.1 82.2 93.5 89.3 84.1 73.3
Any MACE 13.4 15.9 17.8 6.5 10.7 15.9 26.7
All values except n are percent. MI indicates myocardial infarction; CABG, coronary artery bypass grafting; TLPR, target lesion
percutaneous revascularisation; MACE, major adverse clinical events; PS, primary stenting; and GBA, guided balloon angioplasty.
Twelve patients were excluded from the study after the first randomization: 10 patients due to inconsistencies between the
randomization service and investigators, and 2 patients due to missing CFR values.
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Because the costs and benefits of provisional angioplasty were
calculated as weighted averages, bootstrapping techniques were used
to evaluate differences in the balance between costs and benefits
after primary stenting and provisional angioplasty.21,22 A total of
3000 bootstrap samples were drawn iteratively, with replacement
when sample sizes equalled the total number of patients studied.
Odds ratios and 95% confidence intervals are presented; a Breslow-
Day test for homogeneity of odds ratios between subgroups and x2
tests were also applied.
Statistical tests were 2-tailed, with significance stated at the 0.05
level. Uncertainties surrounding cost, benefits, and cost-
effectiveness were addressed by probability ellipses in the “cost-
effectiveness plane.”21
Results
Patient Characteristics
Baseline characteristics of the patients in this trial are
presented in Table 1. There were no significant differences
between patients allocated to primary stenting and to guided
balloon angioplasty. Of the 523 patients randomized to
guided balloon angioplasty, 129 (25%) underwent bailout
stenting at the time of initial dilatation (n5103) or during the
optimization process (n5 26). Of the remaining 394 patients,
382 underwent the second randomization. Twelve were not
subrandomized for technical and logistical reasons.
Procedural Results
Table 2 summarizes the procedural results, and Figure 2
shows the relative roles of DS and CFR in classifying
patients. Optimal results, with an average DS of 2268% and
a CFR of 3.160.6, were achieved in 35% of patients. In the
suboptimal group, DS was 23610% and CFR was 2.060.4.
Additional stenting in patients with optimal balloon angio-
plasty resulted in a DS of 868% and a CFR of 3.360.7; in
patients with suboptimal balloon angioplasty, additional
stenting resulted in a DS of 768% but a CFR of 2.460.7.
TABLE 4. Costs and Event-Free Survival After 12 Months
Unit Cost per
Patient, A PS PA*
Optimal
Stenting
Optimal
Balloon
Suboptimal
Stenting
Suboptimal
Balloon Bailout
No. of patients 97 523 77 107 112 86 129
Procedure and initial
hospitalization
Fixed procedure costs, A 1167 1167 1167 1167 1167 1167 1167
Resource use, Unit per
patient
Guiding catheter 82 1.20 1.20 1.19 1.24 1.21 1.14 1.13
Guidewire 95 1.03 0.55 0.40 0.42 0.56 0.44 0.70
FloWire 483 0.26 1.09 1.12 1.11 1.07 1.07 1.07
Balloon 368 1.52 1.55 1.52 1.27 1.67 1.31 1.78
Mounted stent 817 0.58 0.41 0.57 0.04 0.49 0.07 0.82
Nonmounted stent 454 0.56 0.37 0.49 0.04 0.60 0.05 0.49
Reoperation 1021 0.02 0.03 0.04 0.01 0.04 0.03 0.05
IVUS catheter 545 0.05 0.04 0.03 0.02 0.06 0.09 0.05
Contrast medium, mL 0 249 284 333 253 301 307 307
CCU days 856 0.58 0.62 0.53 0.49 0.58 0.84 0.86
ICU days 941 0.00 0.01 0.00 0.00 0.00 0.03 0.05
Non–CCU/ICU days 305 3.36 2.76 2.43 2.27 3.06 2.40 3.00
Follow-up, Unit per patient
Second interventions 2800 0.16 0.16 0.12 0.19 0.15 0.22 0.15
CABG 8622 0.00 0.02 0.00 0.01 0.01 0.01 0.05
Recatheterization 1934 0.20 0.23 0.27 0.21 0.27 0.31 0.22
Vascular surgery 1157 0.00 0.01 0.00 0.00 0.00 0.00 0.02
CCU days 856 0.22 0.21 0.09 0.18 0.15 0.40 0.35
ICU days 941 0.00 0.03 0.00 0.03 0.02 0.01 0.05
Non–CCU/ICU days 305 1.38 2.62 0.82 2.55 2.72 2.11 2.56
Costs of initial hospitalization, A 4456 4486 4493 3606 4769 4084 5305
Costs of follow-up, A 1420 2055 1139 1927 1995 2352 2330
Total cost, A 5885 6573 5632 5533 6764 6519 7763
Event-free survival, % 86.6 85.6 93.5 84.1 89.3 73.3 82.2
CCU indicates coronary care unit; ICU, intensive care unit; CABG, coronary artery bypass grafting; PS, primary stenting; and PA, provisional angioplasty.
*Costs and effects of the provisional angioplasty group were assessed by calculating a weighted average.
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Primary Stenting Versus Provisional Angioplasty
Table 3 shows the incidence of major adverse cardiac events
in both the initial groups and the 4 subgroups, ranked in
hierarchical order. In general, patients with optimal results
experienced fewer major adverse cardiac events than patients
with suboptimal results, and stented patients fared better than
those undergoing balloon angioplasty alone (Figure 3).
Freedom from these events, which were calculated as
weighted averages, was similar for patients undergoing pri-
mary stenting (86.6%) and provisional angioplasty (85.6%)
(Figure 4). The weight for patients needing bailout stenting
was 129/(12911071112186177) or 25.2%; the weight for
patients stented after a suboptimal result was 38.7% (calcu-
lated as the probability of not needing a bailout stent
[100.0%–25.2%574.8%] multiplied by the probability of a
suboptimal result {[112186]/[7711071112186]551.8%});
and the weight for patients with a stent after an optimal result
was 36.0% (calculated as the probability of not needing a
bailout stent [74.8%] multiplied by the probability of an
optimal result [100%–51.8%548.2%]).
Table 4 presents cost estimates for the 2 initial groups and
4 subgroups. The cost of FloWire in the initial procedure was
only partially covered by the lower stent use. Costs for the
provisional angioplasty group during follow-up were higher
due to longer hospitalizations and surgical revascularization.
After 1 year, the costs of provisional angioplasty outweighed
those of direct stenting by EUR 688. Figure 5 presents the
estimates of costs, benefits, and cost effectiveness. The point
estimate of the incremental cost-effectiveness ratio suggests
that provisional angioplasty is less effective and more
expensive.
Stenting Versus Balloon Angioplasty After the
Second Randomization
The analysis of subrandomized patients in the balloon angio-
plasty group (Figure 6) indicates that stenting was associated
with fewer major adverse cardiac events than balloon angio-
plasty alone in both patients with suboptimal (10.7% versus
26.7%; odds ratio, 3.0; P50.005) and optimal results (6.5%
versus 15.9%; odds ratio, 2.7; P50.066). The Breslow-Day
test for homogeneity of odds ratios was not significant
(P50.865). The higher cumulative costs of balloon angio-
plasty alone during the follow-up period almost matched the
high initial costs of balloon angioplasty followed by stenting.
Discussion
The main result of this study was a lack of significant
difference between clinical outcomes when comparing pri-
mary stenting and provisional balloon angioplasty. However,
with the current unit costs of FloWire and stents, a strategy of
provisional angioplasty is more costly than primary stenting.
Relevance and Critical Appraisal of
Cost-Effectiveness Analysis
Cost considerations dominate many decisions about therapeu-
tic interventions and are very relevant from a societal view-
point. As emphasized in the literature, an independent person
without commercial affiliations must analyze cost-
effectiveness in such studies to avoid financial bias.23 How-
ever, cost-effectiveness analyses are limited by multiple
factors. First, cost data are transient and are affected by
product acceptance, market dynamics, and reimbursement
systems. Second, changing patterns of practice affect the
selection of treatment devices, how they are used, and overall
procedure time. Thus, the costs used here represent only a
snapshot in time. For example, direct stenting without predi-
latation (an increasingly used technique) will undoubtedly
affect cost-effectiveness in the future, but this method of
treatment was not applied here.
Two crucial factors in the present study exerted a major
influence on overall costs: the costs of FloWire and those of
stenting. When the study was designed, its power calculation
was based on market prices in 1996 and the cost estimates
related to bleeding complications and the longer hospital
stays associated with stenting. The reported cost estimates
were based on unit costs in 1999 (costs of primary stenting
versus provisional angioplasty, EUR 5916 versus EUR 6724;
Figure 5. Incremental cost-effectiveness of provisional angio-
plasty vs primary stenting. Outer ellipse defines smallest area
(95% probability) containing incremental costs and effectiveness
of provisional angioplasty compared with primary stenting. Mid-
dle and inner ellipses define smallest areas (50% and 5% prob-
abilities, respectively). Center of ellipse represents point esti-
mate of incremental costs and effects. Prob indicates estimated
probability that cost and effect are in respective quadrant;
MACE, major adverse cardiac events.
Figure 6. Relative risk ratios at 12 months for patients with sub-
optimal or optimal balloon angioplasty who survived event-free
and were randomized to additional stenting or no further treat-
ment. Bars indicate 95% confidence intervals.
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P50.029). However, an application of 1996 unit costs does
not change the conclusion. The absence of expected differ-
ences is mainly because in the year 2000, stenting is no longer
associated with bleeding complications and longer hospital
stays, whereas the bailout rate with the balloon angioplasty
group has increased from 15% to 25%.
Moreover, we did not take into account differences in
procedure time. The time for guided angioplasty in the
present study was 26 minutes longer (mean) than that of
stenting, which further tipped the cost-effectiveness balance
in favor of primary stenting.
The Additional Value of Stenting After Optimal
Angioplasty: A Flow-Mediated Phenomenon?
An unexpected observation in this study was a further
reduction in the rate of major adverse cardiac events in
patients stented after optimal balloon angioplasty. This ob-
servation was made possible by the trial’s double randomiza-
tion design. On the basis of stent-like angioplasty results in
other trials,9,13,24 we had hypothesized no such additional
benefits. However, the perceived benefits of additional stent-
ing may have resulted from a selection process that ignored
the outcome of patients with unsatisfactory or complicated
balloon angioplasty (ie, bailout and suboptimal groups).
Although a similar DS was achieved in all patients stented
after angioplasty (7%), a diminished CFR persisted after
stenting in the suboptimal group (2.4) compared with the
optimal group (3.3). Fewer major cardiac events were ob-
served in the latter group (10.7% versus 6.5%). Further
investigations are needed to fully understand the underlying
mechanisms.
Clinical Relevance of the Findings of This Study
The present study failed to demonstrate a favorable economic
profile for provisional angioplasty (guided by quantitative
angiography and Doppler flow velocity measurements) com-
pared with primary stenting. Indeed, although there was no
significant difference in clinical effectiveness, the data
pointed to higher costs with provisional angioplasty. Thus,
the current data do not provide economic arguments to switch
from primary stenting, even though clinical benefits result
when stenting follows optimal balloon angioplasty. A limita-
tion of our study was the inclusion of patients with only a
single, relatively short lesion. However, it would seem from
a literature survey that the patients studied represented
possibly up to 70% of patients presently treated by percuta-
neous techniques worldwide.25,26
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